Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
11 papers
Recent·Most cited
A. N. Honko, R. Hunegnaw, J. I. Moliva, A. Ploquin, C. N. M. Dulan, T. Murray, D. Carr, K. E. Foulds, J. B. Geisbert, T. W. Geisbert, J. C. Johnson, S. E. Wollen-Roberts, J. C. Trefry, D. A. Stanley, N. J. Sullivan
A single dose of ChAd3-SUDV vaccine protected macaques from lethal SUDV challenge via parenteral and aerosol routes.
bioRxiv · Feb 7, 2024 · PreprintImmunology
J. I. Moliva, S. F. Andrew, B. J. Flynn, D. A. Wagner, K. E. Foulds, M. Gagne, D. R. Flebbe, E. Lamb, S. Provost, J. Marquez, A. Mychalowych, C. Lorag, C. C. Honeycutt, M. R. Burnett, L. McCormick, , Nason
This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.
bioRxiv · Nov 22, 2023 · PreprintImmunology
D. Xu, A. E. Powell, A. Utz, M. Sanyal, J. Do, J. J. Patten, J. I. Moliva, N. J. Sullivan, R. A. Davey, P. S. Kim
This paper designs universal Ebola virus vaccine candidates using hyperglycosylation to focus antibody responses on conserved epitopes, showing cross-neutralizing activity against multiple orthoebolavirus species.
bioRxiv · Oct 14, 2023 · PreprintImmunology
A. W. Freyn, C. Atyeo, P. L. Earl, J. L. Americo, G.-Y. Chuang, H. Natarajan, T. R. Frey, J. Gall, J. I. Moliva, R. Hunegnaw, G. Asthagiri Arunkumar, C. Ogega, A. Nasir, H. Bennett, J. Johnson, , B. Moss
This paper develops an mRNA-lipid nanoparticle vaccine targeting four conserved MPXV surface proteins, showing superior protection against VACV compared to MVA.
bioRxiv · Dec 17, 2022 · PreprintImmunology
J. Misasi, R. R. Wei, L. Wang, A. Pegu, C.-J. Wei, O. Oloniniyi, T. Zhou, J. I. Moliva, B. Zhao, M. Choe, E. S. Yang, Y. Zhang, M. Boruszczak, M. Chen, K. Leung, , N. J. Sullivan
This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.
bioRxiv · Jul 29, 2022 · PreprintImmunology
M. Gagne, J. I. Moliva, K. E. Foulds, S. F. Andrew, B. J. Flynn, A. P. Werner, D. A. Wagner, I.-T. Teng, B. C. Lin, C. Moore, N. Jean-Baptiste, R. Carroll, S. L. Foster, M. Patel, M. Ellis, , Naisan
This study compares B cell responses and protection against Omicron after boosting vaccinated macaques with mRNA-1273 or mRNA-Omicron vaccines, finding comparable immunity and protection.
bioRxiv · Feb 3, 2022 · PreprintImmunology
M. Gagne, K. S. Corbett, B. J. Flynn, K. E. Foulds, D. A. Wagner, S. F. Andrew, J.-P. M. Todd, C. C. Honeycutt, L. McCormick, S. T. Nurmukhambetova, M. E. Davis-Gardner, L. Pessaint, K. W. Bock, B. M. Nagata, M. Minai, , B. S. Graham
This study shows that mRNA-1273 vaccine protection against SARS-CoV-2 Delta in nonhuman primates persists for one year but is delayed and relies on anamnestic antibody responses in the lower airway.
bioRxiv · Oct 23, 2021 · PreprintImmunology
K. S. Corbett, M. Gagne, D. Wagner, S. O'Connell, S. R. Narpala, D. R. Flebbe, S. F. Andrew, R. L. Davis, B. Flynn, T. S. Johnston, C. Stringham, L. Lai, D. Valentin, A. Van Ry, Z. Flinchbaugh, , A Pekosz
mRNA-1273 boosted nonhuman primates show increased neutralizing antibody responses and protection against SARS-CoV-2 beta variant infection.
bioRxiv · Aug 11, 2021 · PreprintImmunology
K. S. Corbett, M. C. Nason, B. Flach, M. Gagne, S. O'Connell, T. S. Johnston, S. N. Shah, V. V. Edara, K. Floyd, L. Lai, C. McDanal, J. R. Francica, B. Flynn, K. Wu, A. Choi, , Leung
This study shows that mRNA-1273 vaccine-induced antibody responses correlate with protection against SARS-CoV-2 infection in nonhuman primates.
bioRxiv · Apr 20, 2021 · PreprintImmunology
K. Wu, A. P. Werner, J. I. Moliva, M. Koch, A. Choi, G. B. E. Stewart-Jones, H. Bennett, S. Boyoglu-Barnum, W. Shi, B. S. Graham, A. Carfi, K. S. Corbett, R. A. Seder, D. K. Edwards
This study evaluates the neutralizing antibody response of mRNA-1273 vaccine against SARS-CoV-2 variants B.1.1.7 and B.1.351 using pseudovirus neutralization assays.
bioRxiv · Jan 25, 2021 · PreprintImmunology
B. Zhang, C. W. Chao, Y. Tsybovsky, O. M. Abiona, G. B. Hutchinson, J. I. Moliva, A. S. Olia, A. Pegu, E. Phung, G. Stewart-Jones, R. Verardi, L. Wang, S. Wang, A. Werner, E. S. Yang, , P. D. Kwong
This paper develops a nanoparticle platform for displaying trimeric antigens, showing that SARS-CoV-2 spike-LuS nanoparticles induce 25-fold higher neutralizing responses than spike alone.
bioRxiv · Jun 11, 2020Immunology